Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors-Reference-Cited by-同舟云学术

Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors

Published:2021 Issue:35 Volume:13 Page:15010-15020
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

McDaid William J.¹²,Lissin Nikolai³,Pollheimer Ellen¹,Greene Michelle¹,Leach Adam¹⁴,Smyth Peter¹,Bossi Giovanna³,Longley Daniel¹,Cole David K.³^ORCID,Scott Christopher J.¹^ORCID

Affiliation:

1. The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK, BT9 7AE

2. Cancer Research UK Manchester Institute, Alderley Park, Congleton Rd, Alderley Edge, Macclesfield, UK, SK10 4TG

3. Immunocore Ltd, 101 Park Dr, Milton, Abingdon, United Kingdom OX14 4RY

4. Institute of Cancer Research, 15 Cotswold Rd, Sutton, London, SM2 5NG, UK

Abstract

High-affinity TCRs offer the potential to target chemotherapeutic drug-loaded nanoparticles specifically to tumour cells expressing tumour-specific peptides minimising off-target effects.

Funder

Health and Social Care Northern Ireland

Medical Research Council

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2021/NR/D1NR04001D

Reference42 articles.

1. Molecular targeted therapy: Treating cancer with specificity

2. Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens